Keywords: Atrial fibrillation, Market forecasts, Bristol-Myers, Pfizer, Bayer, Johnson & Johnson, Eliquis, Xarelto
Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021
Article | 13 November 2012
The atrial fibrillation drug market will experience dramatic growth over the next decade, increasing from $2.7 billion in 2011 to $9.2 billion in 2021 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
